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Summary
Objective: To determine resistance trends including the emergence of extensive drug resistance
(XDR) in Mycobacterium tuberculosis (MTB) isolates from Pakistan.
Methods: This was a retrospective analysis of MTB isolates (January 1990—June 2007) collected
from the four provinces of Pakistan. Standard methods were used to isolate MTB. Susceptibility
against rifampin, isoniazid, streptomycin, ethambutol, ethionamide, capreomycin, cycloserine,
and ciprofloxacin was tested using the agar proportion method, while susceptibility to pyrazi-
namide was determined using BACTEC. Resistance over the study period was assessed using Chi-
square for trend analysis.
Results: Resistance in 15 343 MTB isolates showed a steady increase over the study period; a
significant trend of increasing resistance was noted in three of the four provinces included in the
study. XDR-tuberculosis was first seen in 1998; to date 22 XDR cases have been documented. MTB
resistance was significantly lower (p < 0.001) in patients under 5 and over 60 years of age, and
significantly higher in males than females (p < 0.001). MTB resistance was also higher in
pulmonary than extrapulmonary isolates ( p < 0.001).
Conclusion: This study documenting a steady increase in resistance among MTB isolates and the
emergence of XDR strains is concerning. The data highlight the need to ensure adequate
treatment of cases in order to prevent a further increase in multidrug resistance within the
country. The importance of developing systems for monitoring drug resistance through nation-
wide surveillance is emphasized.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +92 21 4864530/4864531;
fax: +92 21 4934294.
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Tuberculosis (TB) continues to be a worldwide pandemic,
with half of all new cases reported from six Asian countries.1
Pakistan, with a population of over 161 million, ranks 6th inPublished by Elsevier Ltd. All rights reserved.
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181/100 000 and a prevalence rate of 359/100 000 popula-
tion.2 It is estimated that 51% of cases are concentrated in
the province of Punjab, followed by 23% in the province of
Sindh, 15% in the North West Frontier Province (NWFP), and
3.5% in Baluchistan, with the remainder being distributed
within the tribal and northern areas and in Azad Kashmir.
Drug resistance reportedly associated with treatment fail-
ure, relapse,3 complications, and mortality4 presents a
threat to national TB control programs.5 This concern has
been exacerbated with reports of extensive drug resistance
(XDR).6,7 International agencies, including the World Health
Organization (WHO), strongly emphasize the need for infor-
mation on anti-TB drug resistance including XDR from coun-
tries (such as Pakistan) that lack mechanisms for conducting
drug resistance surveys.8
Available local data primarily from laboratory-based stu-
dies relying on small sample sizes report an increasing fre-
quency of multidrug-resistant (MDR) isolates.9—11 However,
such reports require further exploration. We analyzed data
from a tertiary care referral center to assess resistance
trends and in particular to assess the frequency of XDR-TB
in our population.
Materials and methods
Setting
This study was conducted at The Aga Khan University Hospital
(AKUH). The hospital and its clinical laboratory are accre-
dited by the Joint Commission of International Accreditation
(JCIA) and designated as a technical partner of the NTP. The
laboratory participates in external quality control surveys
with the College of American Pathologists (CAP). Mycobac-
terium tuberculosis (MTB) susceptibility has further been
validated by the Supranational Laboratory of the WHO.
The NTP, through its provincial and district level network,
achieved 100% DOTS coverage with a 50% detection rate for
smear-positives in 2006. Diagnosis within the NTP in confor-
mity with the DOTS policy is based on smear microscopy. Drug
susceptibility testing (DST) and second-line therapy are not
offered within the national program as yet. There are only a
few laboratories in the country offering DST for MTB. The Aga
Khan University laboratory has the widest DST network, in the
sense that it receives specimens collected through more than
175 collection units located in major cities and towns across
the country. Specimens for TB cultures are requested by
physicians as required and are received through passive speci-
men collection. All of the specimens collected at each of the
collection units are sent to the main laboratory in Karachi for
TB cultures and DST. Specimens are transported in a controlled
environment to reach the main laboratory within 24 hours of
collection. As such the data presented here include represen-
tation fromdifferent parts of the country. Over the last 4 years
the Aga Khan University received 12 000—15 000 specimens
annually for MTB culture with a 15—20% positivity rate.
In the absence of a national DST program the data pre-
sented here were not collected in a programmed survey of
drug resistance but obtained as part of routine analysis of
specimens submitted to the laboratory between January
1990 and June 2007.Specimen selection
All clinical samples (pulmonary and extrapulmonary) yielding
growth of MTB were selected. Data retrieved from the
centralized database included identification, age, sex, loca-
tion (inpatient or outpatient), year and month of isolation,
specimen type, city from which the specimen was received,
and susceptibility pattern of TB against first- and second-line
agents. Treatment history, however, was not available and
therefore the combined resistance rate was assessed. Dupli-
cate specimens from the same patient were excluded.
Microbiological methods
Isolation of Mycobacterium tuberculosis (MTB)
Isolation of MTB during the study period was performed using
the standard methodology.12 Over the 17.5-year study per-
iod, three different methods of TB culture were used.
Between 1990 and 1996 specimens for TB cultures were
inoculated on Lowenstein—Jensen (LJ) medium (Oxoid).
From 1996 to 2003 both LJ and BACTEC 12B (Becton Dick-
inson) were used, while from 2003 to date both LJ and MGIT
(Becton Dickinson) have been used for all specimens. MTB
was identified by BACTEC NAP TB differentiation test (Becton
Dickinson, USA).
Antimicrobial susceptibility test
Susceptibility testing was performed using the agar propor-
tion method on enriched Middlebrook 7H10 medium (BBL) at
the following concentrations: rifampin 1 mg/ml and 5 mg/ml,
isoniazid 0.2 mg/ml and 1 mg/ml, streptomycin 2 mg/ml and
10 mg/ml, ethambutol 5 mg/ml and 10 mg/ml, ethionamide
5 mg/ml, capreomycin 10 mg/ml, cycloserine 30 mg/ml, and
ciprofloxacin 2 mg/ml.13 Pyrazinamide sensitivity was intro-
duced in 1996 and carried out using the BACTEC 7H12medium
pH 6.0 at 100 mg/ml (BACTEC PZA test medium, Becton
Dickinson, USA).14 During the study period a similar method
of susceptibility testing was used, and MTB H37Rv was used as
the control with each batch tested.
To ensure the selection of high level resistance strains for
the purposes of this study, only resistance to the higher
concentrations was used for the analysis (isoniazid resistance
was defined as resistance to 1 mg/ml, rifampin resistance was
defined as resistance to 5 mg/ml, streptomycin resistance
was defined as resistance to 10 mg/ml, and ethambutol
resistance was defined as resistance to 10 mg/ml). MDR
was defined as resistance to at least isoniazid and rifampin.
Five-drug-resistant MTB was resistant to isoniazid, rifampin,
pyrazinamide, ethambutol, and streptomycin. XDR was
defined as resistance to any quinolones and to one of the
injectable second-line drugs in addition to MDR.15 Our labora-
tory tests four classes of second-line TB drugs: ethionamide,
capreomycin, cycloserine, and ciprofloxacin. Therefore all
MDR-TB isolates resistant to ciprofloxacin and capreomycin
were taken as XDR. Flouroquinolone testing started in 1998,
therefore XDR rates are reported from 1998 to June 2007.
Data management and statistical analysis
Data extracted from the computerized information system of
the hospital were transferred to the statistical software SPSS
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percentages were computed for age groups, gender, and
source of specimen. Mean and standard deviation (SD) was
also reported for age. Associations of age group, gender, and
type of specimen with the first-line drugs and MDR were
assessed using the Chi-square test. The Chi-square test for
trend analysis was also conducted to assess the antimicrobial
resistance trend over the study period. A p-value of less than
5% was considered statistically significant.
Ethical approval
This study was approved by the Ethics Review Committee of
the Aga Khan University, Pakistan.
Results
During the 17.5-year study period, 15 343 MTB were isolated
from patients with a male to female ratio of 1.1:1. The mean
age of the patients with MTB was 36.6 (SD 17.1) years. Of the
isolates, 78.8% (n = 12 085) were from the province of Sindh,
14.6% from Punjab (n = 2237), 5.8% from NWFP (n = 893), and
0.6% from Baluchistan (n = 97).
Resistance trends over the study period
Between 1990 and 2007 an overall increasing trend of resis-
tance was observed against all first-line drugs, including MDR.
Despite periodic fluctuations, such as a decline noted in
2003—2005, the analysis for trend showed the increase in
resistance to be statistically significant ( p for trend <0.001)
(Figure 1).
Due to the higher representation from the province of
Sindh, further analysis was conducted to compare resistance
trends for each province independently. Figure 2 shows that
MDR trends followed the overall pattern of increasing resis-Figure 1 Resistance pattern ofMycobacterium tuberculosis against
RIF, rifampin; PZA, pyrazinamide; STR, streptomycin; ETH, ethambut
rifampin); 5DR, five-drug-resistant. The p-values for trend: MDR (INH
STR, p < 0.001; ETH, p < 0.001. *Number of samples for all the fir
resistance = number of resistant isolates expressed as a percentage
January to June 2007.tance in the provinces of Sindh, Punjab, and NWFP ( p for
trend <0.001). The lack of statistical significance in the case
of Baluchistan ( p for trend = 0.426) in all probability relates
to the small sample size for this province.
Extensive drug resistance
During the study period a total of 22 patients had XDR-TB.
First seen in the year 1998, the highest number of cases with
XDR strains was observed in 2001 (n = 6). XDR strains were
equally distributed by gender and were highest in the age
group 15—44 years (n = 14). No XDR strains were seen in
either the pediatric population or in the extrapulmonary
specimens.
Association of MTB resistance with age and
gender
MTB resistance was significantly lower in patients under 5
years and over 60 years of age ( p-value<0.001) as compared
to the other age groups: 5—14, 15—44, and 45—59 years
(Table 1). Higher resistance rates were noted in isolates from
males ( p <0.001) (Table 2). The difference was also statis-
tically significant for isoniazid, rifampin, pyrazinamide, and
ethambutol ( p < 0.05; data not shown).
Pulmonary and extrapulmonary specimens
Of the isolates studied, 12 104 were pulmonary and 3046
were extrapulmonary (information of source was missing for
193 patients). The proportion of pulmonary vs. extrapulmon-
ary samples was 3.97:1. There was greater representation of
extrapulmonary isolates amongst children: 56.2% of isolates
from children under 5 years of age were from an extrapul-
monary source. Similarly 25.3% of isolates from females were
extrapulmonary as compared to only 15.6% from males.first-line drugs over the study period, 1990—2007. INH, isoniazid;
ol; MDR, multidrug-resistant (resistance to at least isoniazid and
+RIF), p < 0.001; INH, p < 0.001; RIF, p < 0.001; PZA, p < 0.001;
st-line drugs except for pyrazinamide, MDR, and 5DR. Percent
of the total isolates cultured in that year (n). 2007 data are for
Figure 2 Multidrug resistance trends by province, 1990—2007. p-Value for trend <0.001 (Sindh, Punjab, NWFP); p-value for
trend = 0.426 (Baluchistan). Percent resistance = number of resistant isolates expressed as a percentage of the total isolates cultured
in that year (n). Values in the table reflect the total number of MDR for a particular province in a given year. 2007 data are for January to
June 2007.
Table 1 Percent multidrug resistance (MDR) rates in Mycobacterium tuberculosis with regard to age (% calculated where sample
size is >30)
Year Age (years)
<5 5—14 15—44 45—59 >60
na MDR (%)b na MDR (%)b na MDR (%)b n a MDR (%)b na MDR (%)b
1990 0 0 1 0 50 3 (6) 26 0 13 0
1991 2 1 5 1 103 8 (7.8) 41 0 (0) 26 1
1992 0 0 12 0 153 17 (11.1) 59 5 (8.5) 43 4 (9.3)
1993 2 0 10 0 136 18 (13.2) 39 4 (10.3) 42 3 (7.1)
1994 0 0 11 0 196 21 (10.7) 57 4 (7.0) 48 1 (2.1)
1995 1 0 10 1 342 12 (3.5) 74 1 (1.4) 91 0 (0)
1996 4 0 15 0 428 7 (1.6) 149 3 (2.0) 121 0 (0)
1997 7 0 22 0 462 41 (8.9) 129 6 (4.7) 99 2 (2.0)
1998 9 1 33 0 (0) 489 72 (14.7) 134 12 (9.0) 114 7 (6.1)
1999 7 1 29 5 543 140 (25.8) 147 25 (17.0) 94 11 (11.7)
2000 11 1 44 5 (11.4) 684 203 (29.7) 209 41 (19.6) 146 17 (11.6)
2001 4 0 27 10 587 235 (40.0) 159 47 (29.6) 138 27 (19.6)
2002 3 1 30 5 (16.7) 515 188 (36.5) 158 55 (34.8) 105 23 (21.9)
2003 3 0 36 13 (36.1) 854 407 (47.7) 212 101 (47.6) 178 65 (36.5)
2004 3 0 46 17 (37.0) 941 460 (48.9) 245 111 (45.3) 179 54 (30.2)
2005 7 1 55 13 (23.6) 1170 413 (35.3) 337 96 (28.5) 233 35 (15.0)
2006 6 2 65 22 (33.8) 1217 445 (36.6) 332 101 (30.4) 269 53 (19.7)
2007 6 0 45 26 (55.7) 795 299 (37.6) 226 58 (25.7) 158 25 (15.8)
Total c 75 10.7d, e 496 23.8d 9665 30.9d 2733 24.5d 2097 15.6d, e
a Total MTB culture-positive for the category listed.
b Number of MDR isolates (%).
c Information was missing for 277 patients.
d MDR expressed as a percentage of the total positive isolates (n) for that age group.
e MDR significantly lower in age groups<5 years and>60 years ( p< 0.001 by Chi-square test) as compared to age groups 5—14, 15—44, and
45—59 years (overall statistical analysis for the five age groups revealed a p-value of <0.001).
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Table 2 Percent multidrug resistance (MDR) rates in Myco-
bacterium tuberculosis with regard to gender
Year Male Female Total MDR
na MDR(%)b na MDR(%)b
1990 55 3 (5.5) 37 0 (0.0) 3
1991 107 7 (6.5) 74 4 (5.4) 11
1992 172 18 (10.5) 126 13 (10.3) 31
1993 129 13 (10.1) 102 12 (11.8) 25
1994 159 14 (8.8) 156 13 (8.3) 27
1995 265 6 (2.3) 266 8 (3.0) 14
1996 379 8 (2.1) 353 3 (0.8) 11
1997 396 32 (8.1) 365 20 (5.5) 52
1998 441 58 (13.2) 388 38 (9.8) 96
1999 442 116 (26.2) 410 74 (18.0) 190
2000 599 152 (25.4) 512 116 (22.7) 268
2001 484 167 (34.5) 441 154 (34.9) 321
2002 439 153 (34.9) 390 119 (30.5) 272
2003 712 338 (47.5) 581 249 (42.9) 587
2004 748 364 (48.7) 673 279 (41.5) 643
2005 959 329 (34.3) 847 229 (27.0) 558
2006 1024 331 (32.3) 872 293 (33.6) 624
2007 675 216 (32) 565 192 (34.3) 408
Total 8185c 28.4c, d 7158 25.4c, d
a Total MTB culture-positive for the category listed.
b Number of MDR isolates (%).
c MDR significantly higher in males (p-value<0.001, Chi-square
test).
d MDR expressed as a percentage of the total positive isolates
(n) for that gender.
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significantly higher than amongst extrapulmonary isolates
(5.9%). The difference was significant ( p < 0.001, Chi-square
analysis).
Discussion
While TB drug resistance trends are available from a number
of South Asian countries, data from Pakistan are scarce. This
study reports increasing resistance over a 17.5-year period.
The increasing resistance trend was significant for all first-
line agents ( p-value for trend of all five first-line
drugs < 0.001) evaluated as well as for MDR. Further analysis
suggested that the rising trend also held true for three of the
four provinces from where samples were collected.
Pakistan is currently only providing DOTS therapy; DOTS-
plus is not as yet included in the National TB Control Program.
Active surveillance not being possible in the absence of a
treatment facility for MDR-TB, the data presented in this
study were collected through passive case finding. High
resistance rates in this study are therefore likely to be a
result of selection bias due to greater numbers of compli-
cated and treatment failure cases being referred for DST. We
believe that the dependence on passive case finding may also
have contributed to the slight decrease in resistance
observed during the period 2003—2005. Due to this limita-
tion, this study focuses on reporting resistance trends in the
population studied as opposed to prevalence data. Within
this population, the high resistant rates and increasing resis-tance trend are alarming, even though a success rate of 80% is
reported for DOTS in Pakistan. Our data raises the possibility
that a considerable TB population consulting private practi-
tioners is not included within the DOTS program. Our data
further points to the need for a nationwide drug resistance
surveillance program to assess the prevalence of drug resis-
tance within the country. Such a survey should also address
the issue of patient catchment within the NTP program versus
private practitioners and private healthcare providers.
XDR-TB as a complication of inadequately managed MDR
cases has been reported worldwide.16 Recent reports of the
emergence of XDR-TB from India, Iran,17,18 and now also from
Pakistan, are alarming. Moreover, since all six classes of
second-line TB drugs were not tested, it is possible that
the data presented reflect under-reporting of XDR. However,
the observation of an increasing level of resistance in our
data and in particular the evolution of XDR strains is a serious
issue particularly in a low-resource setting such as Pakistan.
Lower TB resistance in isolates from young children and
the elderly has also been reported previously.19—23 Since
resistance in those under 5 years of age is likely to reflect
the level of exposure to and thus cross-transmission of MDR
strains, lower resistance in this age group supports the
hypothesis that most resistance in the population is as a
result of poor compliance or drug delivery as opposed to
transmission.
Higher resistance amongst males is consistent with recent
studies reporting male gender19,20,24 as a risk factor for
resistant TB. Published studies have suggested higher risk
of exposure to resistant strains together with poor compli-
ance in males as contributory factors.25,26 However the
association of drug resistance with gender in our population
has not been investigated, and needs to be further explored.
A greater frequency of extrapulmonary cases is reported
in this study amongst children and in females. The higher
prevalence of extrapulmonary isolates in those aged under 5
years has been previously documented and attributed to
difficulties in obtaining respiratory specimens from children
and hence collection bias.27—29 Female sex has been sug-
gested as an independent risk factor for extrapulmonary
disease;29,30 this link, though supported by data from our
study, is difficult to explain and requires further investiga-
tion.
The lower prevalence of drug resistance and the absence
of XDR within extrapulmonary isolates, in agreement with
published reports,31,32 is encouraging, particularly as obtain-
ing specimens from these patients for culture and sensitivity
testing is difficult.
Conclusions
This study reporting a steady increase in resistance among
MTB isolates from Pakistan and the emergence of XDR strains
is concerning. We further report the highest resistance in
young male adults and in pulmonary cases. A major limitation
of this study was the inability to differentiate primary and
treated cases. Such studies are not possible unless the NTP
includes provision of DOTS-plus within its scope. The rising
resistance trend observed in our population emphasizes the
urgent need for a population-based nationwide drug resis-
tance survey. It further emphasizes the need to ensure
e382 R. Hasan et al.adequate treatment for new cases to prevent the creation of
additional MDR.
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